Frontotemporale Lobärdegeneration – Prägnanztypen, Diagnosekriterien und Therapieansätze

• Literatur

• 1 Gorno-Tempini ML, Hillis AE, Weintraub S et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006-1014
• 2 Rascovsky K, Hodges JR, Knopman D et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456-2477
• 3 Ringholz GM, Appel SH, Bradshaw M et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005; 65: 586-590
• 4 Burrell JR, Kiernan MC, Vucic S et al. Motor neuron dysfunction in frontotemporal dementia. Brain 2011; 134: 2582-2594
• 5 Taylor LJ, Brown RG, Tsermentseli S et al. Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis?. J Neurol Neurosurg Psychiatry 2013; 84: 494-498
• 6 Weih M, Sidiropoulos C, Wiltfang J. Frontotemporale Demenz. Psych up2date 2007; 1: 89-102
• 7 Nass R, Meister I, Haupt W et al. ALS und frontotemporale Demenz – Fallbericht und Literaturübersicht. Fortschr Neurol Psychiatrie 2012; 80: 711-719
• 8 Kipps CM, Davies RR, Mitchell J et al. Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dement Geriatr Cogn Disord 2007; 23: 334-342
• 9 Mion M, Patterson K, Acosta-Cabronero J et al. What the left and right anterior fusiform gyri tell us about semantic memory. Brain 2010; 133: 3256-3268
• 10 Lu PH, Mendez MF, Lee GJ et al. Patterns of brain atrophy in clinical variants of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord 2013; 35: 34-50
• 11 Frisch S, Dukart J, Vogt B et al. Dissociating memory networks in early Alzheimer’s disease and frontotemporal lobar degeneration – a combined study of hypometabolism and atrophy. PLoS One 2013; 8: e55251
• 12 Schroeter ML, Vogt B, Frisch S et al. Dissociating behavioral disorders in early dementia – a FDG-PET study. Psychiatry Res 2011; 194: 235-244
• 13 Woost TB, Dukart J, Frisch S et al. Neural correlates of the DemTect in Alzheimer’s disease and frontotemporal lobar degeneration – a combined MRI & FDG-PET study. NeuroImage Clinical 2013; 2: 746-758
• 14 Ishii K. PET approaches for diagnosis of dementia. Am J Neuroradiol 2014; 35: 2030-2038
• 15 Drzezga A, Förster S. Demenzdiagnostik mit der Amyloid-PET. Der Nuklearmediziner 2012; 35: 82-92
• 16 Vance C, Al-Chalabi A, Ruddy D et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2–21.3. Brain 2006; 129: 868-876
• 17 Pearson JP, Williams NM, Majounie E et al. Familial frontotemporal dementia with amyotrophic lateral sclerosis and a shared haplotype on chromosome 9p. J Neurol 2011; 258: 647-655
• 18 Renton AE, Majounie E, Waite A et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72: 257-268
• 19 Dejesus-Hernandez M, Mackenzie IR, Boeve BF et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245-256
• 20 Pijnenburg YA, Schoonenboom SN, Mehta PD et al. Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2007; 78: 735-737
• 21 Riemenschneider M, Wagenpfeil S, Diehl J et al. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 2002; 58: 1622-1628
• 22 Bibl M, Mollenhauer B, Lewczuk P et al. Cerebrospinal fluid Tau, p-Tau 181 and amyloid-beta(38/40/42) in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord 2011; 31: 37-44
• 23 Verwey NA, Kester MI, van der Flier WM et al. Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis 2010; 20: 445-452
• 24 Steinacker P, Hendrich C, Sperfeld AD et al. Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. J Neural Transm 2009; 116: 1169-1178
• 25 Bian H, Van Swieten JC, Leight S et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008; 70: 1827-1835
• 26 Brunnstrom H, Rawshani N, Zetterberg H et al. Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimer's & Dementia 2010; 6: 104-109
• 27 Hu WT, Chen-Plotkin A, Grossman M et al. Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology 2010; 75: 2079-2086
• 28 Feneberg E, Steinacker P, Lehnert S et al. Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 2014; 15: 351-356
• 29 Steinacker P, Hendrich C, Sperfeld AD et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 2008; 65: 1481-1487
• 30 Ghidoni R, Benussi L, Glionna M et al. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 2008; 71: 1235-1239
• 31 Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 2010; 24: 375-398
• 32 Boxer AL, Knopman DS, Kaufer DI et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013; 12: 149-156
• 33 Finch N, Baker M, Crook R et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 2009; 132: 583-591
• 34 Van Damme P, Van Hoecke A, Lambrechts D et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 2008; 181: 37-41